CN113040291A - Application of PPAR gamma activator in improving environmental stress resistance of aquatic animals - Google Patents
Application of PPAR gamma activator in improving environmental stress resistance of aquatic animals Download PDFInfo
- Publication number
- CN113040291A CN113040291A CN202110373554.6A CN202110373554A CN113040291A CN 113040291 A CN113040291 A CN 113040291A CN 202110373554 A CN202110373554 A CN 202110373554A CN 113040291 A CN113040291 A CN 113040291A
- Authority
- CN
- China
- Prior art keywords
- zebra fish
- stress
- composition
- wild
- ppar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010016731 PPAR gamma Proteins 0.000 title claims abstract description 70
- 102000000536 PPAR gamma Human genes 0.000 title claims abstract description 64
- 239000012190 activator Substances 0.000 title claims abstract description 45
- 241001465754 Metazoa Species 0.000 title claims abstract description 43
- 230000006353 environmental stress Effects 0.000 title claims abstract description 28
- 241000252212 Danio rerio Species 0.000 claims description 105
- 239000000203 mixture Substances 0.000 claims description 71
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 48
- 230000035882 stress Effects 0.000 claims description 35
- 230000004083 survival effect Effects 0.000 claims description 35
- 235000021588 free fatty acids Nutrition 0.000 claims description 27
- 210000004185 liver Anatomy 0.000 claims description 25
- 229960004586 rosiglitazone Drugs 0.000 claims description 24
- XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical compound N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 claims description 18
- 230000008642 heat stress Effects 0.000 claims description 18
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 16
- 230000008645 cold stress Effects 0.000 claims description 15
- 238000001514 detection method Methods 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 230000036542 oxidative stress Effects 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 230000004069 differentiation Effects 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 5
- 210000001789 adipocyte Anatomy 0.000 claims description 4
- 238000009395 breeding Methods 0.000 claims description 4
- 230000001488 breeding effect Effects 0.000 claims description 4
- 229960000516 bezafibrate Drugs 0.000 claims description 3
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 claims description 3
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 claims description 3
- 229950009226 ciglitazone Drugs 0.000 claims description 3
- 229960001214 clofibrate Drugs 0.000 claims description 3
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 239000003674 animal food additive Substances 0.000 claims description 2
- 238000009360 aquaculture Methods 0.000 claims description 2
- 244000144974 aquaculture Species 0.000 claims description 2
- 238000010276 construction Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000000512 lipotoxic effect Effects 0.000 abstract description 15
- 241000251468 Actinopterygii Species 0.000 description 31
- 238000002474 experimental method Methods 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 239000011521 glass Substances 0.000 description 15
- 108091033409 CRISPR Proteins 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 9
- 108020005004 Guide RNA Proteins 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000002440 hepatic effect Effects 0.000 description 6
- 238000010354 CRISPR gene editing Methods 0.000 description 5
- 241001098657 Pterois Species 0.000 description 5
- 239000008399 tap water Substances 0.000 description 5
- 235000020679 tap water Nutrition 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000003209 gene knockout Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 235000012424 soybean oil Nutrition 0.000 description 4
- 239000003549 soybean oil Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 108091092584 GDNA Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000013011 mating Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000006298 dechlorination reaction Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- 108700032225 Antioxidant Response Elements Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 108010065459 CCAAT-Enhancer-Binding Protein-alpha Proteins 0.000 description 1
- 101710168309 CCAAT/enhancer-binding protein alpha Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 241000692870 Inachis io Species 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 241000276569 Oryzias latipes Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 102000007451 Steroid Receptors Human genes 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 229940062672 calcium dihydrogen phosphate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 101150073877 egg-1 gene Proteins 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000013215 result calculation Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 108700024526 zebrafish sox32 Proteins 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K61/00—Culture of aquatic animals
- A01K61/10—Culture of aquatic animals of fish
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K61/00—Culture of aquatic animals
- A01K61/10—Culture of aquatic animals of fish
- A01K61/13—Prevention or treatment of fish diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/137—Heterocyclic compounds containing two hetero atoms, of which at least one is nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/40—Fish
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
- Y02A40/81—Aquaculture, e.g. of fish
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Health & Medical Sciences (AREA)
- Animal Husbandry (AREA)
- Environmental Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Insects & Arthropods (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
Abstract
The invention discloses an application of a PPAR gamma activator in relieving lipotoxicity of aquatic animals and improving the capability of resisting environmental stress of the aquatic animals.
Description
Technical Field
The invention relates to the field of aquaculture, in particular to application of a PPAR gamma activator in relieving lipotoxicity of aquatic animals and improving the capability of resisting environmental stress of the aquatic animals.
Background
The environmental stress refers to environmental stimulation which can cause the animal body to present a "tension state" in the environment, and the common environmental stress comprises low temperature, high temperature, water quality deterioration and the like. The response of fish to environmental stress is a non-specific physiological response. Environmental stress is not a disease in itself, but it is a cause of one or more diseases. Various environmental stresses are generally suffered in the cultivation process of aquatic animals such as fishes, and the aquatic animals are seriously damaged or even die due to the excessive or overlong environmental stresses, which causes serious losses to breeders. Therefore, the method has strong practical value for improving the resistance of aquatic animals such as fishes to environmental stress.
In order to enhance the resistance of aquatic animals to environmental stress and improve the culture yield, the method generally adopts the modes of adding the artificial treatment of river water into a culture pond, periodically disinfecting the water body, adding vitamin C into feed and the like.
Further, peroxisome proliferator-activated receptor gamma (PPAR γ) is a key transcriptional regulator of adipogenesis, and can directly regulate the expression of genes related to adipocyte differentiation and lipid metabolism.
However, as a result of no study, PPAR γ has been associated with the resistance of aquatic animals such as fish against environmental stress, and it is unknown whether or not there is an interaction relationship between them.
Disclosure of Invention
In view of the above technical problems, the present invention provides an application of PPAR γ activator for improving the resistance of aquatic animals against environmental stress, which is to administer PPAR γ activator to aquatic animals (such as fish) to promote fat synthesis, reduce the level of free fatty acid in liver, thereby improving and relieving lipotoxicity, and improving the resistance of aquatic animals (such as fish) under stress conditions.
In order to achieve the purpose, the invention adopts the following technical scheme:
in one aspect, there is provided the use of a PPAR γ activator in the manufacture of a composition for enhancing the ability of an aquatic animal to resist environmental stress, and the composition includes a PPAR γ activator.
Preferably, the PPAR γ activator is contained in an amount of 10-30mg/kg of the composition.
Preferably, the composition is a pharmaceutical composition or an aquatic feed additive or an aquatic animal health product.
Preferably, the composition further comprises a pharmaceutically or feedstuffs or animal health acceptable carrier or excipient.
Preferably, the carrier or excipient is an oleaginous base or a water-soluble base.
Preferably, the PPAR γ activator comprises one or more of rosiglitazone, ciglitazone, bezafibrate and clofibrate.
Preferably, the aquatic animals include fish, and more preferably, the fish is ornamental fish such as zebra fish (commonly called "striped fish"), ribbon medaka (commonly called: peacock fish), red crucian, immortal fish, etc.;
preferably, the improvement of the resistance of the aquatic animals to environmental stress comprises one or more of promotion of differentiation of fat cells, reduction of free fatty acid level, reduction of oxidative stress, improvement of resistance to cold stress, improvement of resistance to heat stress and improvement of resistance to ammonia nitrogen stress.
In one aspect, a composition is provided that can be administered to an aquatic animal and includes a PPAR γ activator.
Preferably, the PPAR γ activator is contained in an amount of 10-30mg/kg of the composition.
Also provided is a method for constructing a zebrafish (Danio rerio) model for improving the ability of aquatic animals to resist environmental stress, comprising the steps of:
s1, knocking out a peroxisome proliferator-activated receptor gamma (PPAR gamma) gene of the zebra fish to obtain mutant zebra fish;
s2, breeding wild zebra fish and mutant zebra fish, detecting tissue samples of the wild zebra fish and the mutant zebra fish, and detecting the resistance of the wild zebra fish and the mutant zebra fish under stress reaction;
s3, dividing wild zebra fish into 2 groups serving as a wild control group and a wild experimental group respectively, and taking mutant zebra fish serving as a mutant experimental group, wherein the wild experimental group and the mutant experimental group are fed with a composition containing a PPAR gamma activator;
and S4, taking tissue samples of the zebra fish of the wild control group, the wild experimental group and the mutant experimental group for detection, and detecting the resistance of each group of zebra fish under stress reaction.
Preferably, the tissue sample detection indicators include: one or more of liver triglyceride, liver free fatty acid and the like, and the resistance detection indexes under stress reaction comprise: survival rate under cold stress, survival rate under heat stress and survival rate under ammonia nitrogen stress.
The invention has at least the following beneficial effects:
the invention improves and relieves lipotoxicity and improves the resistance of aquatic animals (such as fishes) under stress conditions by giving PPAR gamma activators to the aquatic animals (such as fishes) to promote fat synthesis and reduce the level of free fatty acid in the liver.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the description of the embodiments are briefly introduced below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings based on these drawings without creative efforts.
FIG. 1 shows the results of an experiment for evaluating the safety of PPAR γ activator (rosiglitazone);
FIG. 2 is a graph showing the triglyceride content, free fatty acid level and survival rate under cold stress, heat stress and ammonia nitrogen stress in the liver of zebra fish in example 1 after rosiglitazone was added to the composition at 10mg/kg, 20mg/kg and 30mg/kg, respectively;
FIG. 3 is a schematic diagram of the CRISPR/Cas9 technology-based zebra fish PPAR γ gene knockout in example 1;
FIG. 4 is a graph showing triglyceride content, free fatty acid level and survival under cold stress, heat stress, ammonia nitrogen stress in livers of wild type zebra fish and mutant zebra fish in example 2;
FIG. 5 is a graph showing triglyceride content, free fatty acid level and survival under cold stress, heat stress and ammonia nitrogen stress in livers of wild-type control group zebra fish, wild-type experimental group zebra fish and mutant experimental group zebra fish in example 2.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is described in further detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
Example 1:
the embodiment provides application of a PPAR gamma activator in preparing a composition for improving the capability of resisting environmental stress of aquatic animals, wherein the composition comprises the PPAR gamma activator and a carrier or excipient which is acceptable in pharmacy or composition science or animal health care science, and 10-30mg of the PPAR gamma activator is contained in each kg of the composition.
And providing a composition that can be administered to an aquatic animal and contains 10-30mg of a PPAR γ activator per kg of the composition.
The PPAR gamma activator comprises one or more of rosiglitazone, ciglitazone, bezafibrate and clofibrate, and the aquatic animals comprise fish, more preferably the fish is ornamental fish.
Meanwhile, the composition can be in the form of a pharmaceutical composition (including a vaccine) or an aquatic product composition additive or an aquatic animal health product, and the carrier or excipient is an oleaginous base or a water-soluble base.
The term "pharmaceutically or compositionally or animal nutraceutically acceptable carrier or excipient" refers to a carrier for the administration of a therapeutic agent, including various diluents, which are not essential active ingredients per se, and which are not unduly toxic after administration. Suitable carriers are well known to those of ordinary skill in the art.
PPAR γ activator (rosiglitazone) safety assessment experiment:
control compositions were prepared according to the formulations shown in table 1.
TABLE 1 control composition formula
Composition formula (g/kg) | Control |
Casein as Casein | 300 |
Gelatin | 50 |
Corn starch Corn starch | 350 |
Soybean oil | 70 |
Vitamin premix1 | 4 |
Mineral premix2 | 8 |
Choline |
5 |
2, 6-di-tert-butyl-4-methylphenol BHT | 0.2 |
Dimethyl-beta-propionic acid thetin (DMPT) | 1 |
Calcium dihydrogen phosphate Ca (H)2PO4)2 | 10 |
|
40 |
Cellulose | 161.8 |
Total up to | 1000 |
When preparing the experimental composition, rosiglitazone was first dissolved in dimethyl sulfoxide (DMSO) at a weight ratio of DMSO to soybean oil in the above formulation of 1:9, so the amount of DMSO required was calculated from the amount of soybean oil required in the above formulation. Mixing the DMSO in which the rosiglitazone is dissolved with the soybean oil uniformly, mixing the mixture with other components in the formula uniformly, pressing the mixture into strips, airing the strips, crushing the strips, sieving the strips, bagging the strips, and refrigerating the strips to obtain the experimental group composition with the addition amount of the PPAR gamma activator of 20 mg/kg.
The safety evaluation experiment is provided with a control group and an experiment group, each treatment group is provided with 3 parallel treatment groups, 6 transparent glass jars with the volume of about 30L are prepared, and 36 zebra fish are randomly placed in each glass jar.
Before starting the experiment, the initial total body weight of zebrafish per jar was recorded, and the control group was then fed with the composition of the experimental group (i.e. "20 mg/kg" group in fig. 1), which was fed 4-6% of body weight each day, twice a day in the morning and evening (9:00 and 17: 00). Weighing once a week, recalculating daily feeding amount according to body weight, and culturing for four weeks for each group.
During the culture experiment, excrement at the bottom of the tank is sucked away every two days, half of water is replaced, tap water subjected to aeration dechlorination is used for replacing water, the water temperature is kept at 26 +/-5 ℃, the pH value is 7.8, dissolved oxygen is higher than 6.5mg/L, and the 14-hour illumination and 10-hour light cycle at night are maintained. 3 zebra fish (total 6) are respectively taken from the experimental group and the control group and respectively placed in 6 small fish tanks (1 tail in one small tank) with the same size and specification, then the 6 small fish tanks are placed in a behavior instrument together, and the motion trail of each zebra fish is recorded at the same time.
After the culture is finished, 3 zebra fishes are randomly taken from 3 parallel jars of a control group and an experimental group respectively, and 9 zebra fishes are taken from each treatment group. The zebra fish is placed in 20mg/L MS-222 aqueous solution for anesthesia, the liver is collected, the livers of 2-3 zebra fish are mixed into a tube, 4 treatment groups are arranged in parallel, and the zebra fish is preserved at the temperature of minus 80 ℃. Detecting the expression level of apoptosis and inflammation related genes of zebra fish of each treatment group by using Nanjing construction kit, wherein the apoptosis and inflammation related genes comprise: caspase3a (caspase-3 a), bcl2(B cell lymphoma/leukemia-2), il1B (human interleukin 1. beta.), nf- κ B (nuclear factor κ B).
As can be seen from fig. 1, the composition of the experimental group to which 20mg/kg rosiglitazone was added did not affect the average weights of zebrafish at 2 weeks and 4 weeks, and did not significantly affect the expression levels of the 4 genes associated with apoptosis and inflammation, and at the same time, as can be seen from the movement trace of zebrafish, the zebrafish in the control group and experimental group did not have a significant difference in total distance of 5 minutes movement, thereby indicating that the addition of 20mg/kg rosiglitazone to other groups did not affect the growth and movement of zebrafish, and fully indicating that the administration of PPAR γ activators such as zebrafish rosiglitazone is safe.
The effect of the addition of PPAR γ activator (rosiglitazone) on the ability of zebrafish (Danio reio) to resist environmental stress is illustrated below in connection with the examples.
1) Preparation of control and Experimental compositions
Control compositions were prepared according to the formulations shown in table 1 above.
Also, with reference to the contents of the above safety evaluation test section, compositions having PPAR γ activator additive amounts of 10mg/kg (test group composition 1), 20mg/kg (test group composition 2) and 30mg/kg (test group composition 3) were obtained, respectively.
2) Starting a culture experiment, and collecting the liver of the zebra fish after the culture is finished
The breeding experiment comprises four treatment groups, namely a control group, an experiment group 1, an experiment group 2 and an experiment group 3, wherein each treatment group is provided with 3 parallel treatment groups, 12 transparent glass jars with the volume of about 30L are prepared, and 36 zebra fish are randomly placed into each glass jar.
Before the beginning of the culture, the initial total body weight of each jar of zebra fish is recorded, and then the control group is fed with the control group composition, and the experiment group 1, the experiment group 2 and the experiment group 3 are correspondingly fed with the experiment group composition 1, the experiment group composition 2 and the experiment group composition 3, wherein the control group composition is fed according to 4-6% of the body weight every day, and the zebra fish are fed twice in the morning and evening every day (9:00 and 17: 00). Weighing once every two weeks, recalculating daily feeding amount according to the weight, and culturing all the groups for four weeks.
During the culture period, the feces at the bottom of the tank are sucked away every two days, half of the water is replaced, the water is replaced by tap water after aeration and dechlorination, the water temperature is kept at 26 +/-5 ℃, the pH value is 7.8, the dissolved oxygen is higher than 6.5mg/L, and the 14-hour illumination and 10-hour light cycle at night are maintained.
After the culture is finished, 3 zebra fishes are randomly taken from 3 parallel tanks of a control group, an experimental group 1, an experimental group 2 and an experimental group 3 respectively, and 9 zebra fishes are taken from each treatment group. The zebra fish is placed in 20mg/L MS-222 aqueous solution for anesthesia, the liver is collected, the livers of 2-3 zebra fish are mixed into a tube, 4 treatment groups are arranged in parallel, and the zebra fish is preserved at the temperature of minus 80 ℃. The content of triglyceride and the concentration of free fatty acid in the livers of the zebra fish of each treatment group are measured by a Nanjing constructed kit.
3) Respectively carrying out cold stress, heat stress and ammonia nitrogen stress
Before cold stress treatment, 12 glass jars are placed into a biochemical incubator, each 3 glass jars are used as a treatment group, 4 treatment groups are totally placed and marked, each glass jar is adjusted to be in a 15 ℃ refrigeration mode, and then 10 zebra fishes are respectively taken from each glass jar of each treatment group and are respectively placed into corresponding small jars which are marked.
The experiment was started, the number of dead fish was counted every 12h, the survival rate was calculated and reduced by 1 ℃ until all zebrafish dead light in two or more pots in 3 parallel pots of any treatment group or the survival rate had significantly differed by 72 hours after the experiment was performed. Bait feed was stopped throughout the experiment.
Before heat stress treatment, the water bath is adjusted to 27 ℃, and the water bath is put into 12 small isolation tanks (plastic fish tanks with small holes on the periphery for facilitating water flow), and each 3 small isolation tanks are used as a treatment group, and 4 treatment groups are marked. And respectively taking 10 zebra fish from each glass jar of each treatment group, and respectively putting the zebra fish into corresponding marked small isolation jars.
The experiment was started, the temperature was raised by 1 ℃ every half hour until the temperature was raised to 38 ℃, then the water temperature of 38 ℃ was maintained, the number of dead fish was counted every 12h, and the survival rate was calculated until two or more zebra fish in 3 parallel vats of any treatment group all died, or the survival rate after the experiment was run for 72 hours had a significant difference. Bait feed was stopped throughout the experiment.
The ammonia nitrogen stress is that ammonium chloride (analytically pure) is used as an ammonia nitrogen source, the nitrogen concentration determined in the experiment is 85mg/L, namely about 648.85mg of ammonium chloride is added into glass jars with 2L of dechlorinated tap water, 12 glass jars are prepared according to the method, each 3 glass jars are used as a treatment group, 4 treatment groups are provided, 2L of dechlorinated tap water is filled in each glass jar, about 648.85mg of ammonium chloride is added into the tap water, and the treatment groups are marked.
At the beginning of the experiment, 10 zebra fish were taken from each glass jar of each treatment group and put into the 12 marked glass jars with 85mg/L nitrogen concentration.
Counting the number of dead fish every 12h, and calculating the survival rate until two or more zebra fish in 3 parallel vats of any treatment group die completely or the survival rate after the experiment is carried out for 72 hours has a significant difference. During the experiment, the test solution was changed every 24 hours by 50% of the total volume. Bait feed was stopped throughout the experiment.
4) Result calculation analysis
The content of triglyceride in liver and the concentration of free fatty acid are calculated according to a formula given in Nanjing constructed kit instructions, graph pad software is input for drawing after the calculation is completed, SPSS software is used for analyzing whether significant difference exists, the significant difference is set as P <0.05, and the very significant difference is set as P < 0.01.
After the survival data were calculated, the data were also entered into GraphPad software for mapping and analyzed for significant differences using SPSS software.
Survival rate at each time point is the number of live fish/initial total fish at the current time point.
As can be seen from FIG. 2(A), compared with the control group, the addition of 10mg/kg and 20mg/kg of rosiglitazone in the composition can significantly increase the content of triglyceride in the liver of zebra fish, and the effect of adding 20mg/kg of rosiglitazone is more obvious.
As can be seen from fig. 2(B), the addition of rosiglitazone to the composition was helpful to reduce the liver free fatty acid level of zebra fish compared with the control group, and the difference was significant when 20mg/kg of rosiglitazone was added.
As can be seen from fig. 2(C), the addition of rosiglitazone at 10mg/kg and 20mg/kg to the composition significantly improved the survival rate of zebrafish treated for 36 hours and 48 hours under cold stress, compared to the control group, wherein the effect of adding rosiglitazone at 20mg/kg was more significant.
As can be seen from fig. 2(D), the survival rate of zebrafish under heat stress for 60 hours can be significantly improved by adding 20mg/kg rosiglitazone to the composition; in addition, under the condition of heat stress for 72 hours, the survival rate of the zebra fish can be improved by adding 10mg/kg and 20mg/kg of rosiglitazone.
As can be seen from FIG. 2(E), the survival rates of the zebra fish under ammonia nitrogen stress for 60 hours and 72 hours can be remarkably improved by adding 20mg/kg of rosiglitazone.
Therefore, the principle that the addition of PPAR-gamma activators such as rosiglitazone and the like in the composition can relieve lipotoxicity and improve the resistance of the zebra fish to cold stress, heat stress and ammonia nitrogen stress can be fully demonstrated as follows:
PPAR-gamma is a ligand-dependent transcription factor, and PPAR-gamma activators such as rosiglitazone bind to the ligand binding domain of PPAR gamma and steroid receptor co-activator-1 (SRC-1) to form a ternary complex, thereby activating PPAR gamma. After activated, PPAR gamma can induce the expression of a plurality of genes related to lipid synthesis and promote the expression of CCAAT enhancer binding protein alpha (C/EBP alpha), and also can induce the expression of genes related to triglyceride uptake and storage, thereby promoting the differentiation of fat cells. In addition, PPAR γ can enhance the expression of lipoprotein lipase and free fatty acid transporters, such as fatty acid transporters and fatty acid translocators, thereby promoting the uptake of free fatty acids released from circulating lipoproteins, activating antioxidant response elements and antioxidant-related gene expression, and maintaining the redox homeostasis of cells.
It has been reported that elevated levels of free fatty acids, especially saturated free fatty acids, may play a key role in lipotoxicity mechanisms. If the excess free fatty acids are unable to synthesize triglycerides, the level of free fatty acids in the cells will increase, which can lead to lipotoxicity and oxidative stress, affecting the metabolic balance of the body.
After PPAR gamma is activated by activator such as rosiglitazone, on one hand, the PPAR gamma can promote the differentiation of preadipocytes and the intake of free fatty acid, and finally store the free fatty acid in the form of triglyceride, on the other hand, the PPAR gamma can reduce oxidative stress, thereby relieving the lipotoxicity of the organism. Lipotoxicity is known to produce oxidative stress, and environmental stress leads to cell or animal death associated with oxidative stress, and reducing oxidative stress can improve resistance of cells or animals to stress.
Example 2:
the embodiment provides a method for constructing a zebrafish (Danio rerio) model for improving the environmental stress resistance of aquatic animals, which comprises the following steps:
s1, knocking out a peroxisome proliferator-activated receptor γ (PPAR γ) gene of zebra fish to obtain a mutant zebra fish, in this embodiment, the PPAR γ gene of zebra fish is mainly knocked out based on CRISPR/Cas9 technology, which specifically includes the following steps:
the CRISPR/Cas9 target is designed by using an online tool ZiFiT target Version 4.2, the target sequence is GGGCTTCGGCCTGAGCGCTC, and a sequence is added before and after the target: TAATACGACTCACTATAGGGGCTTCGGCCTGAGCGCTCGTTTTAGAGCTAGAAATAGC, constructing CRISPR/Cas9 target sequence, and connecting the CRISPR/Cas9 target sequence into sgRNA (single guide RNA) plasmid;
and (2) performing PCR amplification by using the sgRNA plasmid as a template and the sgRNA-R as a downstream primer, wherein the PCR amplification system is as follows: template 1. mu.l, 10 XBuffer 5. mu.l, F1 primer (upstream primer, obtained by conventional primer design software) 2. mu.l, R1 primer (downstream primer) 2. mu.l, dNTP 5. mu.l, Taq enzyme 0.5. mu.l, ddH2O34.5. mu.l, 50. mu.l in total;
the PCR amplification procedure was as follows: 94 ℃ for 5min, 94 ℃ for 30s, 56 ℃ for 30s, 72 ℃ for 15s (35 cycles), 72 ℃ for 5min, 4 ℃ for 1 h;
obtaining gDNA (genomic DNA) by PCR amplification, tapping and recovering, and purifying the gDNA;
transcription is carried out by using a Thermo T7 high-yield transcription kit, and the transcription system is as follows: NTP 8. mu.l (each 2. mu.l), 5 XBuffer 4. mu.l, gDNA template 5.5. mu.l, T7 Enzyme 2. mu.l, RNase inhibitor 0.5. mu.l, total 20. mu.l to obtain gRNA;
the transcription program is: placing in water bath at 37 ℃ for 6 h; b. adding 1.5 mul DNase into each tube, mixing uniformly, and carrying out water bath at 37 ℃ for 15 min;
after transcription is finished, 30 mu l of enzyme-free water and 31 mu l of 8M lithium chloride are added into each EP tube, the mixture is uniformly mixed, precipitation is carried out overnight at the temperature of minus 20 ℃, gRNA is precipitated, and the gRNA is washed by 75% ethanol and then dried;
dissolving gRNA with enzyme-free water, mixing gRNA with Cas9 protein (prepared now), and injecting zebra fish embryo by the following injection system: gRNA 0.2 μ l, Cas9 protein 0.5 μ l, Cas9 Buffer 0.3 μ l, total 1 μ l, gRNA final concentration of 400ng/μ l;
when injecting embryo, the injection pressure is adjusted to 20-40; laying roe, and adding needle 1.5 μ l; the injection volume (bleb) was egg 1/10 size; injection as close to the animal spine as possible;
designing a primer on NCBI according to a target point, wherein the primer sequence of PPAR gamma (transcript number: NM-131467) is F: CAACTGCAGATACATGCCGC, R: TGGTAGCTGTGGAAGAAGCG; after PCR amplification, SDS gel running or sequencing is carried out by a company, and F0-generation zebra fish with mutation is screened;
mating F0-generation zebra fish carrying mutation with wild zebra fish to generate F1 generation, screening out the mutation of the same type in F1 generation, mating male and female to obtain F2-generation zebra fish, screening out homozygote from F2-generation zebra fish, adding 6 base pairs on a target site of the homozygote and deleting 2 non-adjacent base pairs, and enabling PPAR gamma of the zebra fish to encode protein of 527 amino acids; however, the translation product of the gene knockout line with the premature stop codon only contains 72 amino acid residues, the PPAR gamma gene knockout target is shown in figure 3, and finally, the F2 generation homozygous zebra fish is subjected to male and female mating to obtain a large number of F3 generation zebra fish, namely, mutant zebra fish with the PPAR gamma gene knockout, namely F3 generation zebra fish;
s2, breeding the wild zebra fish and the mutant zebra fish for the same time under the same condition, and then respectively taking tissue samples of the wild zebra fish and the mutant zebra fish to detect and detect the resistance of the wild zebra fish and the mutant zebra fish under stress reaction; preferably, the tissue sample detection indicators include: one or more of liver triglyceride, liver free fatty acid and the like, and the resistance detection under stress reaction comprises the following steps: one or more of survival rate under cold stress, survival rate under heat stress and survival rate under ammonia nitrogen stress; the index detection and the resistance detection under stress reaction are the same as in example 1, and are not described again;
as shown in fig. 4, compared with wild zebra fish, the liver triglyceride level of the mutant zebra fish is significantly reduced, and the free fatty acid level of the liver is significantly increased, so that liver lipotoxicity is caused, and meanwhile, compared with wild zebra fish, the resistance of the mutant zebra fish to cold stress, heat stress and ammonia nitrogen stress is significantly reduced, so that the resistance of the fish to environmental stress is significantly related to lipotoxicity caused by imbalance of fat metabolism of the fish for the first time;
s3, setting three processing groups: the method comprises the following steps of (1) setting N (such as 3) parallel treatment groups in each treatment group, preparing 3 x N culture containers with the same specification, randomly putting M (such as 30) zebra fish into each culture container of the wild type control group, randomly putting M zebra fish into each culture container of the wild type experimental group and randomly putting M zebra fish into each culture container of the mutant type experimental group, wherein N and M are positive integers and can be set according to experimental needs;
recording the initial total body weight of each zebra fish, and then feeding a control group composition (such as a composition prepared by a formula in table 1) to a wild-type control group, and feeding an experimental group composition added with a PPAR gamma activator to both the wild-type experimental group and the mutant experimental group, wherein the PPAR gamma activator is added in an amount of 10-30mg/kg in the experimental group composition, in this embodiment, the experimental group composition is one or more of the experimental group composition 1, the experimental group composition 2 and the experimental group composition 3, preferably, the PPAR gamma activator is added in the same amount in the experimental group compositions fed to the wild-type experimental group and the mutant experimental group, and the amounts of the PPAR gamma activator in the experimental group compositions are 20 mg/kg;
feeding each treatment group according to 4-6% of the weight every day, feeding twice (9:00 and 17: 00) in the morning and evening every day, weighing once every two weeks, recalculating daily feeding amount according to the weight, and culturing for four weeks;
and S4, taking tissue samples of the zebra fish of the wild control group, the wild experimental group and the mutant experimental group for detection, and detecting the resistance of each group of zebra fish under stress reaction, wherein the detection indexes of the tissue samples and the detection indexes of the resistance under stress reaction are the same as those of S2, and are not repeated here, and the detection result is shown in FIG 4.
As can be seen from fig. 5(a) - (B), compared to the wild-type control group, the wild-type experimental group has significantly increased hepatic triglyceride content and significantly decreased hepatic free fatty acid level, while the mutant experimental group has significantly decreased hepatic triglyceride content and significantly increased hepatic free fatty acid level, because the mutant experimental group lacks PPAR γ gene in zebrafish, and cannot relieve lipid toxicity even though PPAR γ activator is added, while the wild-type control group and the wild-type experimental group have the opposite results to those in fig. 4, that is, the PPAR γ activator is added to the composition to increase hepatic triglyceride and simultaneously decrease hepatic free fatty acid level, which just proves that the PPAR γ activator can effectively relieve lipid toxicity.
Further, as can be seen from fig. 5(C), at 60 hours of cold stress, the survival rate of the wild type experimental group was significantly increased and the survival rate of the mutant type experimental group was significantly decreased compared to the wild type control group, and at 24, 36 and 48 hours of cold stress, the survival rate of the wild type experimental group was more increased and the survival rate of the mutant type experimental group was less decreased compared to the wild type control group; as can be seen from fig. 5(D), the survival rates at 60 hours of heat stress of the wild-type experimental group were significantly increased and at 36 and 48 hours of heat stress of the wild-type control group, while the survival rates at 48 and 60 hours of heat stress of the mutant experimental group were significantly decreased and at 12, 24 and 36 hours of heat stress of the mutant experimental group were decreased, as compared with the wild-type control group; as can be seen from fig. 4(E), compared with the wild-type control group, the survival rate of the wild-type experimental group under the ammonia nitrogen stress for 60 hours is greatly increased, and the survival rates under the ammonia nitrogen stresses for 24 hours, 36 hours and 48 hours are increased; compared with a wild control group, the survival rate of the mutant experimental group is obviously reduced under the ammonia nitrogen stress of 48 hours and 60 hours, and the survival rate under the ammonia nitrogen stress of 24 hours and 36 hours is in a descending trend. The result trend is similar to triglyceride and liver free fatty acid, that is, the survival rate of the zebra fish under the stress condition cannot be improved even if the PPAR gamma activator is added due to the lack of the PPAR gamma gene in the zebra fish of the mutant experimental group, while the resistance under the stress condition can be improved by the wild experimental group through the addition of the PPAR gamma activator.
Therefore, as can be seen from the results in fig. 5, the PPAR γ gene is closely related to the resistance of fish to environmental stress and lipotoxicity caused by imbalance of fat metabolism, and the addition of the PPAR γ activator in the composition can significantly improve and relieve the lipotoxicity, improve the resistance of fish under stress conditions, and improve the model building success of the zebra fish model with the capability of aquatic animals to resist environmental stress.
In conclusion, the invention discovers for the first time that the PPAR gamma gene is closely related to the resistance of aquatic animals such as fish to environmental stress and lipotoxicity caused by imbalance of fat metabolism, and the PPAR gamma activator is added into the composition to promote fat synthesis and reduce the level of free fatty acid in liver, so as to improve and relieve the lipotoxicity and improve the resistance of the aquatic animals such as fish under stress conditions.
The technical features of the above embodiments 1-2 can be combined arbitrarily, and the combined technical solutions all belong to the protection scope of the present application. The foregoing shows and describes the general principles, essential features, and advantages of the invention. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, which are merely illustrative of the principles of the invention, but that various changes and modifications may be made without departing from the spirit and scope of the invention, which fall within the scope of the invention as claimed. The scope of the invention is defined by the appended claims and equivalents thereof.
Claims (10)
1. Use of a PPAR γ activator in the manufacture of a composition for improving the ability of an aquatic animal to resist environmental stress, wherein the composition comprises a PPAR γ activator.
2. The use of claim 1, wherein the improvement of the ability of the aquatic animal to resist environmental stress comprises one or more of promoting differentiation of adipocytes, reducing free fatty acid levels, reducing oxidative stress levels, improving resistance to cold stress, improving resistance to heat stress, and improving resistance to ammonia nitrogen stress.
3. A composition that can be administered to an aquatic animal, wherein the composition comprises a PPAR γ activator.
4. The composition according to claim 3, comprising 10-30mg of PPAR γ activator per kg of the composition.
5. The composition of claim 3, further comprising a pharmaceutically or feedstuffs or animal health acceptable carrier or excipient.
6. The composition of claim 3, wherein the composition is a pharmaceutical composition or an aquaculture feed additive or an aquatic animal health product.
7. The composition of claim 3, wherein the PPAR γ activator comprises one or more of rosiglitazone, ciglitazone, bezafibrate, and clofibrate.
8. A construction method of a zebra fish model for improving the environmental stress resistance of aquatic animals is characterized by comprising the following steps:
s1, knocking out PPAR gamma genes of the zebra fish to obtain mutant zebra fish;
s2, breeding wild zebra fish and mutant zebra fish, detecting tissue samples of the wild zebra fish and the mutant zebra fish, and detecting the resistance of the wild zebra fish and the mutant zebra fish under stress reaction;
s3, taking wild zebra fish as a wild control group and a wild experimental group respectively, and taking mutant zebra fish as a mutant experimental group, wherein the wild experimental group and the mutant experimental group are both fed with a composition added with a PPAR gamma activator;
and S4, taking tissue samples of the zebra fish of the wild control group, the wild experimental group and the mutant experimental group for detection, and detecting the resistance of each group of zebra fish under stress reaction.
9. The method of claim 8, wherein the detection of the indicators of the tissue sample comprises: one or more of liver triglyceride, liver free fatty acid, etc.
10. The method of claim 8, wherein the measure of resistance under stress comprises: survival rate under cold stress, survival rate under heat stress and survival rate under ammonia nitrogen stress.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110373554.6A CN113040291A (en) | 2021-04-07 | 2021-04-07 | Application of PPAR gamma activator in improving environmental stress resistance of aquatic animals |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110373554.6A CN113040291A (en) | 2021-04-07 | 2021-04-07 | Application of PPAR gamma activator in improving environmental stress resistance of aquatic animals |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113040291A true CN113040291A (en) | 2021-06-29 |
Family
ID=76518891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110373554.6A Pending CN113040291A (en) | 2021-04-07 | 2021-04-07 | Application of PPAR gamma activator in improving environmental stress resistance of aquatic animals |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113040291A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070232647A1 (en) * | 2004-05-25 | 2007-10-04 | Goetze Leopold F | Use of Ppar Agonists to Treat Ruminants |
CN103931897A (en) * | 2013-08-22 | 2014-07-23 | 华中农业大学 | Feed additive for reducing freshwater fish body fat content and preparation method thereof |
CN110402893A (en) * | 2019-06-20 | 2019-11-05 | 中山大学 | A kind of preparation and its application of Nrf2 gene delection zebra fish mutant |
-
2021
- 2021-04-07 CN CN202110373554.6A patent/CN113040291A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070232647A1 (en) * | 2004-05-25 | 2007-10-04 | Goetze Leopold F | Use of Ppar Agonists to Treat Ruminants |
CN103931897A (en) * | 2013-08-22 | 2014-07-23 | 华中农业大学 | Feed additive for reducing freshwater fish body fat content and preparation method thereof |
CN110402893A (en) * | 2019-06-20 | 2019-11-05 | 中山大学 | A kind of preparation and its application of Nrf2 gene delection zebra fish mutant |
Non-Patent Citations (2)
Title |
---|
刘颖: "冷应激对猪脂肪、肝脏、心脏与肾脏组织中PPARγ2 mRNA及蛋白表达的影响", 《中国兽医学报》 * |
李晓芸: "PPARγ激动剂通过Nrf2 介导的抗氧化通路改善体内外高脂诱导的氧化应激和炎症反应", 《胃肠病学》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Soliman et al. | The effect of dietary ascorbic acid supplementation on hatchability, survival rate and fry performance in Oreochromis mossambicus (Peters) | |
Promya et al. | The effects of Spirulina platensis and Cladophora algae on the growth performance, meat quality and immunity stimulating capacity of the African Sharptooth Catfish (Clarias gariepinus). | |
Francis et al. | Dietary supplementation with a Quillaja saponin mixture improves growth performance and metabolic efficiency in common carp (Cyprinus carpio L.) | |
BR112018000847B1 (en) | PROCESS FOR PRODUCING A THRAUSTOCHYTRID BIOMASS, USES OF A BIOMASS OBTAINED BY THE PROCESS, FEED AND LIVESTOCK FEED | |
CN107279477A (en) | The formula and processing method of a kind of Penaeus Vannmei biological feedstuff of high usage | |
Chen et al. | Starch to protein ratios in practical diets for genetically improved farmed Nile tilapia Oreochromis niloticus: Effects on growth, body composition, peripheral glucose metabolism and glucose tolerance | |
Tong et al. | Effects of feeding level and C/N ratio on water quality, growth performance, immune and antioxidant status of Litopenaeus vannamei in zero–water exchange bioflocs-based outdoor soil culture ponds | |
CN102132776B (en) | All-natural feed additive for crustacean and preparation method thereof | |
CN103518948B (en) | Environment-friendly compound feeds capable of improving fertility of sciaenops ocellatus parent fish | |
Wang et al. | The comparative studies on growth rate and disease resistance between improved grass carp and common grass carp | |
Zhang et al. | Comparative study on growth, digestive function and intestinal microbial composition of female Chinese mitten crab Eriocheir sinensis selected at different growth stages in rice-crab culture systems | |
Nandi et al. | Reproductive performance of carp, Catla catla (Ham.), reared on a formulated diet with PUFA supplementation | |
Wei et al. | Digestive enzyme and alkaline phosphatase activities during the early stages of Silurus soldatovi development | |
CN102125544B (en) | Inducer for activating expression of fish lipid metabolism control gene and application thereof | |
Li et al. | The success of yellow catfish aquaculture in China: From rare wild fish to popular farmed fish | |
CN116478882A (en) | Preparation method of acid-producing mixed bacteria preparation capable of improving sheep daily gain and feed conversion rate | |
CN113040291A (en) | Application of PPAR gamma activator in improving environmental stress resistance of aquatic animals | |
Ayoola et al. | Comparative study of piscine and non-piscine pituitary extract and ovulin for inducing spawning in catfish (Clarias gariepinus) | |
CN108849645A (en) | A kind of freshwater fish culturing method | |
Qiao et al. | CRISPR/Cas9 establishment-mediated targeted mutagenesis in Macrobrachium nipponense | |
CN111990295A (en) | Method for breeding two batches of channel catfishes in one year | |
CN110477218A (en) | A kind of nutrition prescription preventing the Yellow River carp hemorrhage and preparation method | |
Legros et al. | Effects of insulin on oxygen uptake of Acetabularia mediterranea | |
CN110074283A (en) | Improve compound formulation and the preparation of ocean bivalve shellfish maturity of fish gonads and immunity | |
JP2593794B2 (en) | Formula feed for fish farming |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |